HK1142607A1 - Thiazolium salt compound and use of treating disease related with protein aging - Google Patents
Thiazolium salt compound and use of treating disease related with protein agingInfo
- Publication number
- HK1142607A1 HK1142607A1 HK10109165.8A HK10109165A HK1142607A1 HK 1142607 A1 HK1142607 A1 HK 1142607A1 HK 10109165 A HK10109165 A HK 10109165A HK 1142607 A1 HK1142607 A1 HK 1142607A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- salt compound
- disease related
- treating disease
- thiazolium salt
- protein aging
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102116577A CN101684106B (zh) | 2008-09-22 | 2008-09-22 | 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1142607A1 true HK1142607A1 (en) | 2010-12-10 |
Family
ID=42039079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10109165.8A HK1142607A1 (en) | 2008-09-22 | 2010-09-24 | Thiazolium salt compound and use of treating disease related with protein aging |
Country Status (6)
Country | Link |
---|---|
US (1) | US8338616B2 (zh) |
EP (1) | EP2341048B1 (zh) |
JP (1) | JP6050586B2 (zh) |
CN (1) | CN101684106B (zh) |
HK (1) | HK1142607A1 (zh) |
WO (1) | WO2010031248A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014098869A1 (en) * | 2012-12-20 | 2014-06-26 | Colgate-Palmolive Company | Oral care composition containing ionic liquids |
MX2015007879A (es) * | 2012-12-20 | 2015-09-21 | Colgate Palmolive Co | Composicion para el cuidado oral. |
CN104277011A (zh) | 2013-07-09 | 2015-01-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻唑内盐类化合物及其治疗蛋白老化相关疾病的用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185334A (en) * | 1989-07-31 | 1993-02-09 | Schering Corporation | 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use |
EP1327887A3 (en) * | 1995-01-18 | 2008-12-10 | Synvista Therapeutics, Inc. | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products |
US6777557B2 (en) * | 2001-02-07 | 2004-08-17 | Peter C Ulrich | Method and composition for rejuvenating cells, tissues organs, hair and nails |
PE20030968A1 (es) * | 2002-02-28 | 2004-01-12 | Novartis Ag | Derivados de 5-feniltiazol como inhibidores de cinasas |
CN100349881C (zh) * | 2003-04-02 | 2007-11-21 | 深圳市东阳光实业发展有限公司 | 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途 |
GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
CN101007789B (zh) | 2006-01-27 | 2014-08-20 | 北京摩力克科技有限公司 | 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途 |
-
2008
- 2008-09-22 CN CN2008102116577A patent/CN101684106B/zh not_active Expired - Fee Related
-
2009
- 2009-09-15 EP EP09813969A patent/EP2341048B1/en not_active Not-in-force
- 2009-09-15 WO PCT/CN2009/001036 patent/WO2010031248A1/zh active Application Filing
- 2009-09-15 US US13/120,009 patent/US8338616B2/en not_active Expired - Fee Related
- 2009-09-15 JP JP2011527183A patent/JP6050586B2/ja not_active Expired - Fee Related
-
2010
- 2010-09-24 HK HK10109165.8A patent/HK1142607A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP6050586B2 (ja) | 2016-12-21 |
EP2341048A4 (en) | 2012-02-29 |
EP2341048B1 (en) | 2013-03-06 |
US20110178141A1 (en) | 2011-07-21 |
US8338616B2 (en) | 2012-12-25 |
CN101684106A (zh) | 2010-03-31 |
CN101684106B (zh) | 2013-06-12 |
WO2010031248A1 (zh) | 2010-03-25 |
JP2012502929A (ja) | 2012-02-02 |
WO2010031248A8 (zh) | 2011-05-05 |
EP2341048A1 (en) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160859T1 (hr) | Modificirani proteini rsv f i postupci njihove upotrebe | |
EP2250282A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES | |
EP2250184A4 (en) | TREATMENT OF CHRONIC PAIN WITH ZINC FINGER PROTEINS | |
HK1172896A1 (zh) | 化合物和使用方法 | |
HK1161094A1 (zh) | 化合物和使用方法 | |
HK1153152A1 (zh) | 埃博霉素 在治療包括阿爾茨海默氏症在內的 相關疾病中的應用 | |
HK1146894A1 (zh) | 用於治療指甲疾病的組合物和方法 | |
EP2262754A4 (en) | MINOCYCLINE COMPOUNDS AND METHODS OF USE THEREOF | |
EP2346521A4 (en) | PEPTIDES AND METHODS OF USE | |
HK1173457A1 (zh) | 蛋白晶體和交聯晶體及其使用方法 | |
PT2310042E (pt) | Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena | |
PL2358214T3 (pl) | Zastosowanie kantaksantyny i/lub 25-OH D3 dla poprawy wylęgowości u drobiu | |
EP2377891A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY | |
IL213703A0 (en) | Compounds and methods for the treatment of pain and other diseases | |
HK1157228A1 (en) | Compositions and methods of treating amyloid disease | |
GB2458868A8 (en) | Treatment of protein aggregation diseases | |
HK1142607A1 (en) | Thiazolium salt compound and use of treating disease related with protein aging | |
IL202114A0 (en) | Treatment of allergic disease with immunomodulator compounds | |
EP2328908A4 (en) | TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF | |
ZA201104722B (en) | Animal treatment formulation and methods of use | |
EP2265117A4 (en) | INHIBITORS OF PROTEIN PHOSPHATASE-1 AND USES THEREOF | |
IL208275A0 (en) | Corl-derived collagen and methods of farming same | |
TH0801002895A (th) | C3b แอนติบอดี และวิธีการสำหรับการป้องกันและการบำบัดความผิดปกติที่เกี่ยวข้องกับคอมพลีเมนท์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190927 |